Wissenschaftliche Ergebnisse der Deutschen Tiefsee-Expedition auf dem Dampfer "Valdivia" 1898-1899. Im Auftrage des Reichsamtes des Innern hrsg. von Carl Chun [et al.]

bd. 14, T. Spezieller

Wissenschaftliche Ergebnisse der Deutschen Tiefsee-Expedition auf dem Dampfer "Valdivia" 1898-1899. Im Auftrage des Reichsamtes des Innern hrsg. von Carl Chun [et al.]

bd. 14, L. 1, Tafeln

Fauna arctica : eine Zusammenstellung der arktischen Tierformen mit besonderer Berücksichtigung des Spitzbergen-Gebietes auf Grund der Ergebnisse der Deutschen Expedition in das Nördliche Eismeer im Jahre 1898 Unter Mitwirkung zahlreicher Fachgenossen hrsg. von Fritz Römer und Fritz Schaudinn. Nach ihrem Tode fortgesetzt von August Brauer und Walther Arndt.

Bd.3 (1903-1904)

Estudo do gênero Rhopalias stiles & Hassall, 1898 (Trematoda, Rhopaliasidae)

Os autores fazem um estudo de todas as espécies do gênero Rhopalias Stiles & Hassall, 1898, ratificando quatro espécies e invalidando duas. Ficando assim o gênero com as espécies R. coronatus (Rudolphi, 1819), R. horridus (Diesing, 1850), R. baculifer Braun, 1901 e R. macracanthus Chandler, 1932, as quais são no presente trabalho bem caracterizadas com descrições, quadros comparativos e figuras. Nesta oportunidade aproveitam para determinar todo material pertencente ao gênero depositado na Coleção Helmintológica do Instituto Oswaldo Cruz.

'Greek' and 'Roman' in Latin Medical Texts. Studies in Cultural Change and Exchange in Ancient Medicine : [Proceedings of the 10th International Conference "Ancient Latin Medical Texts", Lausanne, 2010, November 3rd-6th November]

Latin medical texts transmit medical theories and practices that originated mainly in Greece. This interaction took place through juxtaposition, assimilation and transformation of ideas. 'Greek' and 'Roman' in Latin Medical Texts studies the ways in which this cultural interaction influenced the development of the medical profession and the growth of knowledge of human and animal bodies, and especially how it provided the foundations for innovations in the areas of anatomy, pathology and pharmacology, from the earliest Latin medical texts until well into the medieval world.

Status of Iowa Women Report, 6th Edition

Report on the Iowa Commission on the Status of Iowa Women for 2001

Report of Recommendations to Iowa State University of Science and Technology on the Review of Selected General and Application Controls over the University's Accounts Receivable System, April 6th - May 14th 2004

State University Audit Report

Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.

BACKGROUND: Uveal melanoma exhibits a high incidence of metastases; and, to date, there is no systemic therapy that clearly improves outcomes. The anticytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) antibody ipilimumab is a standard of care for metastatic melanoma; however, the clinical activity of CTLA-4 inhibition in patients with metastatic uveal melanoma is poorly defined. METHODS: To assess ipilimumab in this setting, the authors performed a multicenter, retrospective analysis of 4 hospitals in the United States and Europe. Clinical characteristics, toxicities, and radiographic disease burden, as determined by central, blinded radiology review, were evaluated. RESULTS: Thirty-nine patients with uveal melanoma were identified, including 34 patients who received 3 mg/kg ipilimumab and 5 who received 10 mg/kg ipilimumab. Immune-related response criteria and modified World Health Organization criteria were used to assess the response rate (RR) and the combined response plus stable disease (SD) rate after 12 weeks, after 23 weeks, and overall (median follow-up, 50.4 weeks [12.6 months]). At week 12, the RR was 2.6%, and the response plus SD rate was 46.%; at week 23, the RR was 2.6%, and the response plus SD rate was 28.2%. There was 1 complete response and 1 late partial response (at 100 weeks after initial SD) for an immune-related RR of 5.1%. Immune-related adverse events were observed in 28 patients (71.8%) and included 7 (17.9%) grade 3 and 4 events. Immune-related adverse events were more frequent in patients who received 10 mg/kg ipilimumab than in those who received 3 mg/kg ipilimumab. The median overall survival from the first dose of ipilimumab was 9.6 months (95% confidence interval, 6.3-13.4 months; range, 1.6-41.6 months). Performance status, lactate dehydrogenase level, and an absolute lymphocyte count ≥ 1000 cells/μL at week 7 were associated significantly with survival. CONCLUSIONS: In this multicenter, retrospective analysis of 4 hospitals in the United States and Europe of patients with uveal melanoma, durable responses to ipilimumab and manageable toxicity were observed.